⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL80492 | 0.70 | — | — | |
| SCHEMBL31409638 | 0.67 | — | — | |
| SCHEMBL17686774 | 0.59 | — | — | |
| SCHEMBL14795773 | 0.56 | — | — | |
| SCHEMBL1024758 | 0.52 | — | — | |
| SCHEMBL4271079 | 0.49 | — | — | |
| SCHEMBL6569977 | 0.49 | — | — | |
| SCHEMBL22407244 | 0.44 | — | — | |
| SCHEMBL37682 | 0.42 | — | — | |
| SCHEMBL19975905 | 0.42 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9757364-B2 | Naphthyridine derivative compounds | ASTEX THERAPEUTICS LTD (GB) | 2017-09-12 | — | — | US | disclosed |
| US-9737544-B2 | Compounds | ASTEX THERAPEUTICS LIMITED (GB) | 2017-08-22 | — | — | US | disclosed |
| US-20170105978-A1 | NEW COMPOUNDS | ASTEX THERAPEUTICS LIMITED (GB) | 2017-04-20 | — | — | US | disclosed |
| US-20170000781-A1 | QUINOLINES AS FGFR KINASE MODULATORS | ASTEX THERAPEUTICS LIMITED (GB) | 2017-01-05 | — | — | US | disclosed |
| US-9527844-B2 | Naphthyridine derivative compounds | ASTEX THERAPEUTICS LIMITED (GB) | 2016-12-27 | — | — | US | disclosed |
| US-9439896-B2 | Quinolines as FGFR kinase modulators | ASTEX THERAPEUTICS LTD (GB) | 2016-09-13 | — | — | US | disclosed |
| US-20160235744-A1 | SUBSTITUTED PYRIDO[2,3-b]PYRAZINES AS FGFR KINASE INHIBITORS | ASTEX THERAPEUTICS LIMITED (GB) | 2016-08-18 | — | — | US | disclosed |
| US-20160220564-A1 | SUBSTITUTUED QUINOXALINES AS FGFR KINASE INHIBITORS | ASTEX THERAPEUTICS LIMITED (GB) | 2016-08-04 | — | — | US | disclosed |
| US-20160213677-A1 | NEW COMPOUNDS | ASTEX THERAPEUTICS LIMITED (GB) | 2016-07-28 | — | — | US | disclosed |
| US-20160108034-A1 | NAPHTHYRIDINE DERIVATIVE COMPOUNDS | ASTEX THERAPEUTICS LIMITED (GB) | 2016-04-21 | — | — | US | disclosed |
| US-9309241-B2 | Naphthyridine derivative compounds | ASTEX THERAPEUTICS LTD (GB) | 2016-04-12 | — | — | US | disclosed |
| US-9303029-B2 | Substituted quinoxalines as FGFR kinase inhibitors | ASTEX THERAPEUTICS LTD (GB) | 2016-04-05 | — | — | US | disclosed |
| US-9303030-B2 | Compounds | ASTEX THERAPEUTICS LIMITED (GB) | 2016-04-05 | — | — | US | disclosed |
| US-20150239883-A1 | NEW COMPOUNDS | ASTEX THERAPEUTICS LIMITED (GB) | 2015-08-27 | — | — | US | disclosed |
| US-20150057293-A1 | NEW COMPOUNDS | ASTEX THERAPEUTICS LIMITED (GB) | 2015-02-26 | — | — | US | disclosed |
| US-20150031669-A1 | ANTICANCER BENZOPYRAZINES VIA THE INHIBITION OF FGFR KINASES | ASTEX THERAPEUTICS LIMITED (GB) | 2015-01-29 | — | — | US | disclosed |
| US-20140296236-A1 | QUINOLINES AS FGFR KINASE MODULATORS | ASTEX THERAPEUTICS LIMITED (GB) | 2014-10-02 | — | — | US | disclosed |
| US-20140288053-A1 | ANTICANCER PYRIDOPYRAZINES VIA THE INHIBITION OF FGFR KINASES | ASTEX THERAPEUTICS LIMITED (GB) | 2014-09-25 | — | — | US | disclosed |
| US-20100130503-A1 | NEW FLUORENE DERIVATIVES, COMPOSITIONS CONTAINING THE SAME AND USE THEREOF AS INHIBITORS OF THE PROTEIN CHAPERONE HSP 90 | SANOFI-AVENTIS (FR) | 2010-05-27 | — | — | US | disclosed |
| US-20100041662-A1 | Heterocyclic compounds as antiinflammatory agents | FERRAND SANDRINE | 2010-02-18 | — | — | US | disclosed |